What it sells
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Business model breakdown
Workflow: what inputs become what output?
LiliumX platform combines synthetic protein biology, high-throughput functional screening and AI to discover bispecific antibody-drug conjugates with "V-gate" logic; three oncology programs (VLN1 NSCLC/solid, VLN2 CRC, VLN3 pan-cancer, plus one unannounced) in discovery to preclinical.
Economics: what it saves and how it charges
UnverifiedPre-revenue biotech; value from pipeline assets and licensing/collaboration, funded by venture rounds (pre-A financing news).
Distribution: how it reaches customers
Partnering: invites collaboration on its assets and discovery engine via LinkedIn or connect@valinktx.com.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.